2 United States sites
1 France site
2 to 53 Years
Observational
All
Other
Unknown
This is a multi-center, long-term safety and efficacy follow-up study for subjects with
sickle cell disease who have been treated with ex vivo gene therapy drug product in bluebird
bio-sponsored clinical studies. After completing the parent clinical study (approximately 2
years), eligible subjects will be followed for an additional 13 years for a total of 15 years
post-drug product infusion. No investigational drug product will be administered in the
study.
– Provision of written informed consent for this study by subject, or as applicable,
subject’s parent(s)/legal guardian(s)
– Treated with drug product for therapy of sickle cell disease in a bluebird
bio-sponsored clinical study
– Able to comply with study requirements
– There are no exclusion criteria for this study